PC
APTO

PA Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

PA Capital’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$447K Buy
165
+51
+45% +$127K 0.31% 111
2020
Q2 		$323K Buy
+114
New +$368K 0.23% 120

Other funds holding APTO

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PA Capital's APTO Position: Q3 2020 in Review

PA Capital increased its Aptose Biosciences, Inc. (APTO) stake by 45% in Q3 2020, buying an estimated $127K and bringing the position to 165 shares worth $447K. The position accounts for 0.31% of the portfolio, ranked #111.

PA Capital first reported a position in APTO in Q2 2020 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2020.

  • PA Capital held 165 shares of Aptose Biosciences, Inc. worth $447K as of Q3 2020.
  • PA Capital bought 51 Aptose Biosciences, Inc. shares in Q3 2020, an estimated $127K.
  • Aptose Biosciences, Inc. made up 0.31% of PA Capital's portfolio in Q3 2020, its #111 holding.
  • PA Capital first reported a position in Aptose Biosciences, Inc. in Q2 2020 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.